This page brings together the European Medicines Agency's (EMA) latest information on cancer. It lists:
Lynparza is a cancer medicine used for: continuing treatment after initial treatment of high-grade (fast-growing) cancers of the ovaries, fallopian tubes (which connect the ovaries to the womb), and...
Talvey is a cancer medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) and has not responded to treatment (refractory). It is...
This is a summary of the European public assessment report (EPAR) for Herzuma. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It...
This is a summary of the European public assessment report (EPAR) for Strimvelis. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use...
Revlimid is a medicine used for the treatment of certain cancers and serious conditions affecting blood cells and bone marrow, namely multiple myeloma, myelodysplastic syndromes and mantle cell and...
14 new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended 14 medicines for approval at its July 2023 meeting. The CHMP recommended granting a marketing authorisation for Abrysvo (bivalent, recombinant), a vaccine...
Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its March 2023 meeting. The CHMP recommended authorising the COVID-19 vaccine Bimervax (previously COVID-19 Vaccine HIPRA)...
Eight new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended granting a marketing authorisation for Akeega (niraparib/abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer with...
Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its December 2022 meeting. The CHMP recommended granting a conditional marketing authorisation for the advanced therapy...
EMA has recommended a conditional marketing authorisation in the European Union (EU) for Tecvayli (teclistamab) for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies,...
EMA’s human medicines committee, CHMP, has recommended that Rubraca (rucaparib camsylate) should no longer be used as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come...
The twelfth Multi-Stakeholder Paediatric Oncology Strategy Forum, jointly organised by Accelerate...
The third Cancer Medicines Forum took place on the 20th December 2022 and looked at challenges...
The EMA's Cancer Medicines Forum (CMF) aims to explore how EMA can contribute towards addressing...
This first meeting of EMA's Cancer Medicines Forum looked at challenges around research into...